61 related articles for article (PubMed ID: 11501176)
21. The inhibitory effect of tannic acid on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes.
Yao HT; Chang YW; Lan SJ; Yeh TK
Food Chem Toxicol; 2008 Feb; 46(2):645-53. PubMed ID: 17950511
[TBL] [Abstract][Full Text] [Related]
22. Clomipramine N-demethylation metabolism in human liver microsomes.
Wu ZL; Huang SL; Ou-Yang DS; Xu ZH; Xie HG; Zhou HH
Zhongguo Yao Li Xue Bao; 1998 Sep; 19(5):433-6. PubMed ID: 10375803
[TBL] [Abstract][Full Text] [Related]
23. Characterization of hepatic drug-metabolizing activities of Bama miniature pigs (Sus scrofa domestica): comparison with human enzyme analogs.
Li J; Liu Y; Zhang JW; Wei H; Yang L
Comp Med; 2006 Aug; 56(4):286-90. PubMed ID: 16941956
[TBL] [Abstract][Full Text] [Related]
24. In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam.
Tang J; Amin Usmani K; Hodgson E; Rose RL
Chem Biol Interact; 2004 Apr; 147(3):319-29. PubMed ID: 15135087
[TBL] [Abstract][Full Text] [Related]
25. Phenacetin deacetylase activity in human liver microsomes: distribution, kinetics, and chemical inhibition and stimulation.
Kudo S; Umehara K; Hosokawa M; Miyamoto G; Chiba K; Satoh T
J Pharmacol Exp Ther; 2000 Jul; 294(1):80-8. PubMed ID: 10871298
[TBL] [Abstract][Full Text] [Related]
26. [Enzyme kinetics of ligustilide metabolism in rat liver microsomes].
Qian M; Shi LF; Hu JH
Yao Xue Xue Bao; 2009 Apr; 44(4):395-400. PubMed ID: 19545058
[TBL] [Abstract][Full Text] [Related]
27. Catalyzation of cocaine N-demethylation by cytochromes P4502B, P4503A, and P4502D in fish liver.
Arinç E; Bozcaarmutlu A
J Biochem Mol Toxicol; 2003; 17(3):169-76. PubMed ID: 12815613
[TBL] [Abstract][Full Text] [Related]
28. [Metabolism of 3-cyanomethyl-4-methyl-DCK, a new anti-HIV candidate, in human intestinal microsomes].
Zhuang XM; Wen YY; Li H; Deng JT; Kong WL; Tian XT; Cui SL; Xie L
Yao Xue Xue Bao; 2010 Sep; 45(9):1116-22. PubMed ID: 21351567
[TBL] [Abstract][Full Text] [Related]
29. Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.
Zhao XJ; Ishizaki T
Br J Clin Pharmacol; 1997 Nov; 44(5):505-11. PubMed ID: 9384469
[TBL] [Abstract][Full Text] [Related]
30. A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition.
Zhao XJ; Ishizaki T
Eur J Drug Metab Pharmacokinet; 1999; 24(3):272-8. PubMed ID: 10716067
[TBL] [Abstract][Full Text] [Related]
31. The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline.
Hu X; Ni J; Gao N; Ye Z; Hu G; Cai J; Qian J
Chem Biol Interact; 2022 Oct; 366():110123. PubMed ID: 36007633
[TBL] [Abstract][Full Text] [Related]
32. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs.
Henricsson S; Lindholm A; Aravoglou M
Pharmacol Toxicol; 1990 Jan; 66(1):49-52. PubMed ID: 2308907
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo evaluation of hypothermia on pharmacokinetics and pharmacodynamics of nimodipine in rabbits.
Fei YX; Zhang TH; Zhao J; Ren H; Du YN; Yu CL; Wang Q; Li S; Ren TL; Jian Q; Fei SY; Zhang ZQ; Zhang Y
J Int Med Res; 2018 Jan; 46(1):335-347. PubMed ID: 28851258
[TBL] [Abstract][Full Text] [Related]
34. Species difference in nisoldipine oxidation activity in the small intestine.
Komura H; Yasuda M; Yoshida NH; Sugiyama Y
Drug Metab Pharmacokinet; 2002; 17(5):427-36. PubMed ID: 15618694
[TBL] [Abstract][Full Text] [Related]
35. Ultra-structural aspects of the liver following the administration of TAO.
Caramia FG
Quad Antibiot; 1975 Jun; ():57-67. PubMed ID: 1088737
[No Abstract] [Full Text] [Related]
36. Drug metabolism in liver disease.
Howden CW; Birnie GG; Brodie MJ
Pharmacol Ther; 1989; 40(3):439-74. PubMed ID: 2646653
[No Abstract] [Full Text] [Related]
37. [Therapeutic use of TAO in odontostomatology].
Fraysse E; Fraysse H
Chir Dent Fr; 1967 Jan; 37(4):55-9. PubMed ID: 5297316
[No Abstract] [Full Text] [Related]
38. Determination of the physical safety factor of potential pharmacological agents.
Korol B; Lang WJ
J Pharm Sci; 1965 Oct; 54(10):1555-6. PubMed ID: 5295920
[No Abstract] [Full Text] [Related]
39. Nimodipine: drug metabolism and pharmacokinetic profile.
Al-Omar MA
Profiles Drug Subst Excip Relat Methodol; 2005; 31():371-5. PubMed ID: 22469047
[No Abstract] [Full Text] [Related]
40. Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatin.
Lee CK; Choi JS; Choi DH
Indian J Pharmacol; 2012; 44(5):624-8. PubMed ID: 23112426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
